LEADER 01194nam--2200361---450- 001 990006070760203316 005 20150910110310.0 035 $a000607076 035 $aUSA01000607076 035 $a(ALEPH)000607076USA01 035 $a000607076 100 $a20150910d--------km-y0itay50------ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<> battaglia del Garigliano dell'anno 915 ed i monumenti che la ricordano$econ prefazione di Raffaele Castrichino$fPietro Fedele 210 $a[Minturno]$cDirezione didattica di Minturno-Primo circolo$d[s.d.] 215 $aVII, 35 p.$d28 cm 225 2 $aNuova collana minturnese 410 0$12001$aNuova collana minturnese 454 1$12001 606 0 $aBattaglia del Garigliano <915>$2BNCF 676 $a945.62302 700 1$aFEDELE,$bPietro$0434805 702 1$aCASTRICHINO,$bRaffaele 801 0$aIT$bsalbc$gISBD 912 $a990006070760203316 951 $aFC.OE. 999$b1129 FCil$cFC.OE.$d00345812 959 $aBK 969 $aFCIL 979 $aGENEROSO$b90$c20150910$lUSA01$h1103 996 $aBattaglia del Garigliano dell'anno 915 ed i monumenti che la ricordano$91489639 997 $aUNISA LEADER 05221nam 2200625Ia 450 001 9910146099803321 005 20170809165237.0 010 $a1-282-02189-3 010 $a9786612021893 010 $a3-527-62597-6 010 $a3-527-62598-4 035 $a(CKB)1000000000724781 035 $a(EBL)481803 035 $a(OCoLC)476313717 035 $a(SSID)ssj0000262837 035 $a(PQKBManifestationID)11205118 035 $a(PQKBTitleCode)TC0000262837 035 $a(PQKBWorkID)10270942 035 $a(PQKB)11048707 035 $a(MiAaPQ)EBC481803 035 $a(PPN)19456987X 035 $a(EXLCZ)991000000000724781 100 $a20090520d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTumor-associated antigens$b[electronic resource] $eidentification, characterization, and clinical applications /$fedited by Olivier Gires and Barbara Seliger 210 $aWeinheim $cWiley-VCH$dc2009 215 $a1 online resource (386 p.) 300 $aDescription based upon print version of record. 311 $a3-527-32084-9 320 $aIncludes bibliographical references and index. 327 $aTumor-Associated Antigens : Identification, Characterization, and Clinical Applications; Contents; List of Contributors; Part One Tumor-associated Antigens (TAAs): Subclasses of TAAs; 1 T Cell Antigens in Cancer; 1.1 Introduction; 1.2 Generation of T-cell Epitopes; 1.2.1 Subclasses of Tumor-associated T-cell Antigens; 1.2.1.1 Unique Tumor Antigens; 1.2.1.2 Cancer Testis Antigens; 1.2.1.3 Differentiation Antigens; 1.2.1.4 Overexpressed Antigens; 1.3 Identification of T-cell Antigens and their Epitopes; 1.3.1 T-cell Antigens for Cancer Immunotherapy - How are Candidates Selected? 327 $a1.4 ConclusionsReferences; 2 Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines; 2.1 Introduction; 2.2 Tumor Antigen Classes; 2.2.1 Oncofetal Antigens; 2.2.2 Oncogenes as Tumor Antigens; 2.2.3 Overexpressed Normal Molecules as Tumor Antigens; 2.2.4 Cancer-Testis (CT) Antigens; 2.2.5 Minor Histocompatibility Antigens (mHAgs) as Tumor Antigens; 2.2.6 Human Melanoma Antigens; 2.2.7 Human Glioma Antigens and Immunosurveillance in the CNS; 2.2.8 Heat Shock Proteins, Efficient Carriers of Tumor Antigens 327 $a2.2.9 Dendritic Cells, Efficient Cross-presenters of Tumor Antigens2.2.10 Spontaneous and Vaccine-induced Immunity and the Tumor Microenvironment; 2.3 Summary; References; Part Two Methods to Detect TAAs; 3 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part I: SEREX; 3.1 Introduction; 3.2 The SEREX Approach; 3.2.1 Identification of Human Tumor Antigens by SEREX; 3.2.2 Specificity of Human Tumor Antigens; 3.2.2.1 Shared Tumor Antigens; 3.2.2.2 Differentiation Antigens; 3.2.2.3 Antigens Encoded by Mutated Genes; 3.2.2.4 Viral Genes 327 $a3.2.2.5 Overexpressed Genes3.2.2.6 Amplified Genes; 3.2.2.7 Splice Variants of Known Genes; 3.2.2.8 Cancer-related Autoantigens; 3.2.2.9 Non-cancer-related Autoantigens; 3.2.2.10 Products of Underexpressed Genes; 3.2.3 Significance of Antibodies against SEREX Antigens; 3.2.4 Reverse T Cell Immunology; 3.2.5 Functional Significance of Human Tumor Antigens; 3.2.6 The Human Cancer Immunome; 3.2.7 Perspectives for Vaccine Development; 3.3 Conclusions; References; 4 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part II: Proteomex and AMIDA; 4.1 Introduction 327 $a4.1.1 A Humoral Response against Self-antigens: The Notion of Tumor-associated Antigens4.2 Implementation of Serum Antibodies: Serological Screening Technologies; 4.2.1 PROTEOMEX, alias SERPA and SPEARS; 4.2.1.1 PROTEOMEX Technology and its 'Pros' and 'Cons'; 4.2.1.2 Candidate Biomarkers Identified by PROTEOMEX; 4.2.1.3 Implementation of Candidate Biomarkers in the Clinic; 4.2.2 AMIDA; 4.2.2.1 Autologous AMIDA; 4.2.2.2 Allo-AMIDA; 4.2.3 Advantages and Disadvantages of AMIDA; 4.3 AMIDA Antigens and Clinical Application; 4.3.1 Diagnostic TAAs Detected with AMIDA Screening 327 $a4.3.2 Therapeutic Markers 330 $aThe first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies.The result is a must-have for biologists and oncologists in science, clinics and industry. 606 $aTumor antigens 606 $aTumors$xImmunological aspects 615 0$aTumor antigens. 615 0$aTumors$xImmunological aspects. 676 $a616.994079 701 $aGires$b Olivier$0880096 701 $aSeliger$b Barbara$0880097 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910146099803321 996 $aTumor-associated antigens$91965167 997 $aUNINA